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Abstract
The withdrawal of several blockbuster drugs due to severe adverse effects 
and the failure of several developed drugs in clinical trials raised questions about 
the efficacy of current approaches of drug discovery. Moreover, the limitation 
of resources and the long and costive process of drug discovery made a lot of 
pharmaceutical companies to employ drug repurposing strategies to get new 
insights about activities that were not considered during their initial discovery. 
The development of therapeutics for treatment of dermatological condition is not 
considered as priority although it affects the lifestyle of thousands of people around 
the world. Serendipity and observations have contributed significantly in this field 
but immerse efforts have been exerted to find systematic methods to identify new 
indications for drugs, especially with the unprecedented progress in molecular biol-
ogy and omics. So, in this chapter, we will emphasize on different approaches used 
for drug repositioning and how it was applied to find new therapeutics for different 
dermatoses.
Keywords: drug repositioning, alopecia, psoriasis, acne, hirsutism, 
hyperpigmentation
1. Introduction
In the early years of this century, it was expected that revolutionary develop-
ment in industry and technology will allow an unprecedented opportunities for 
drug discovery and development; however, the disappointing rate of drug approval 
in the last 20 years shed the light on the urgent need to reassess the efficiency of 
current strategies of drug discovery.
Despite the large amount of investment that has been put in drug develop-
ment, several drug candidates fail to pass due to pharmacokinetic issues or severe 
side effects that mainly are not demonstrated until clinical phases, which lead to 
extreme economic loss to pharmaceutical companies that might spend more than 
billion dollars in the process.
These facts were not overlooked by pharmaceutical industries or academia; so, 
they started to apply a new strategy that embraces new application of approved 
drugs rather than starting from scratch, which is known as drug repositioning. 
While the term was first coined in 2004, the approach has already led to the discov-
ery of several therapeutic agents in the last century; however, serendipity, trials, 
and errors were the main players in most of these cases.
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No. Studies for discovery of new indications for natural products Ref
Compounds Indication
1. Compounds from frankincense Anti-herpes [1]
2. Frankincense oil Immunomodulatory 
activity
[2]
3. Myrrh standardized extract Schistosomicidal [3]
4. Free-B-ring flavonoids Colon cancer [4]
5. Anti-neoplaston A-10 Immune-modulatory in 
breast cancer patients
[5]
6. Ricinine alkaloids analogs Oral squamous cell 
carcinoma
[6]





8. Curcumin Iron accumulation in liver [8]




10. Bi-aryl methyl eugenol analogs Breast cancer invasion 
inhibitors
[10]
Studies for discovery of new target for natural products
Compounds/extract Targets `
1. Flavonoids containing an 
alpha-keto group
Tyrosinase inhibitors [11]
2. Cycloartane glycoside Lactate dehydrogenase 
inhibitor
[12]
3. Betulinic acid analogs Topoisomerase inhibitors [13]
4. Gingerol derivatives LTA4H inhibitory activity [14]
5. Curcumin derivative Alpha-amylase inhibitory [15]




Studies of natural product repositioning in FAB-Lab.
This means that harnessing our highly advanced tools of molecular biology and 
computational techniques would guarantee the rediscovery of new indications for 
already approved drugs, which will not only increase our arsenal of therapeutic 
agents but also will drastically decrease the time and costs of the whole process.
Moreover, this approach could help for finding therapeutic solutions for orphan 
diseases or clinical conditions that affects low number of population which are usu-
ally neglected by pharmaceutical corps as in the case of dermatologic therapeutics due 
to the low prevalence of many dermatoses and the inappropriate estimation of the 
burden of psychological and physical impact of skin disorders on the quality of life.
Indeed, the field of dermatology covers wide range of disorders, but this means 
that drug repurposing strategy may be uniquely successful, hence the broad variety of 
pathophysiological process affecting the skin. In that aspect, the liver research labora-
tory (FAB-Lab, Faculty of Pharmacy, Mansoura University, Mansoura, Egypt) has 
utilized several approaches for not only optimization and enhancing the therapeutic 
effect of commonly available natural products but also recognizing novel applica-
tion for them so that one therapeutic agent could be used for treatment of several or 
complex conditions (Table 1). In this chapter, we will review different strategies for 
drug repositioning and their application in dermatological and cosmeceutical field.
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2. Drug repositioning strategies
Drug repositioning is achieved by understanding of molecular mechanisms of 
drug action and by identification of the interacting proteins of the drug. In many 
cases, molecular mechanism of drug action is poorly understood or completely 
unknown. The drug action can be observed by identification of drug targets and 
their specific interactions, drug-induced change in expression of a specific gene and 
the associated pathways, and change in disease phenotypes.
Current approaches for drug repositioning come from the so-called “drug 
action spectrum” concept as shown in Figure 1, which is based on three paradigms, 
namely, target-centric, drug-centric, and disease-centric repositioning. The first 
and second modules are closely related and usually applied interchangeably; the 
target-centric module focuses on finding new indication for the already established 
target; for example, the discovery of the role of androgenic receptor in hair loss 
allowed the repurposing of finasteride for treatment of androgenic alopecia.
Drug-centric module aims in finding a new target for therapeutic agent, experi-
mental or abandoned drugs; for example, the notorious thalidomide, which was 
firstly indicated for treatment of nausea and caused the phocomelia crisis, has been 
repurposed for treatment of myeloma and several dermatological conditions related 
to immune diseases.
These types of repositioning use computational ligand- and structure-based 
techniques [12, 13], chemical proteomics [16, 17], and off-target screening to 
identify potential therapeutic applications; so, we will explain the theory behind its 
approach and its application in drug repositioning.
In the third module, the repurposing depends on the similarity of pathophysi-
ological nature of diseases; for example, different types of cancers or different 
autoimmune diseases which allow the expansion of drug to a closely related 
indication so that extensive analysis of the associated molecular targets may not be 
required. Nevertheless, this type of repositioning strategy is the most observed type 
Figure 1. 
The concept of drug action spectrum in drug repositioning is based on three paradigms, namely, drug-centric, 
target-centric, and disease-centric repositioning. In the first and second approaches, computational approaches 
are used extensively to identify novel targets for compounds that were used for different applications. Omics, 
data mining, and meta-analysis of clinical trials could also be used to analyze the relationship between diseases 
and novel molecular targets that was previously investigated in different diseases.
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in drug repurposing field; it is worthy to note that retrospective analysis of several 
repurposing cases could be explained exclusively by drug-target interaction [18].
The main tools used for applying disease-centric repositioning are gene or 
protein expression profiling [14, 15], phenotypic screening [11], clinical observa-
tions [19], side effect analysis [20], and data mining and neural networks [21, 22]. 
In the following section, we will shed the light on the application of these tools in 
drug repositioning, especially in dermatology.
2.1 Application of drug-target interaction in drug repositioning
2.1.1 Ligand- and structure-based approaches
Ligand-based approaches are usually employed when no structural information 
about the target under investigation is available. They are not only used for virtual 
screening but also for lead optimization [17]. The key concept in ligand-based 
approaches is to determine common structural features or descriptors that could 
be found in compounds with the same pharmacological activity; therefore, phar-
macophoric function groups which are necessary to maintain the activity could be 
elucidated (Figure 2) [19].
In structure-based approach, the 3D structure of biological target is used to 
recognize how an active compound bind to its active site; hence, molecular dock-
ing could be used for identifying other drugs that can bind to the active site in 
similar fashion [20]. It is worthy to note that such approach could be used also for 
identifying the ability of drugs to bind to diverse types of targets, which is known as 
target fishing or inverse docking; this could be achieved by docking drug of interest 
against database of targets of clinical significance (Figure 3) [21].
Indeed, drug repositioning cases derived from this approach are still limited, but 
it has been extensively used to give insights on the mode of action of natural products 
and the rationale behind their use in traditional medicine. For example, ricinoleic 
acid (1), acteoside (2), amentoflavone (3), quercetin-3-O-rutinoside (4), and 
hinokiflavone (5) were expected to be prostaglandin D2 synthase inhibitors by inverse 
docking, which could explain their use in herbal preparation for hair loss treatment 
[22]; another study revealed that the anti-inflammatory effect of Bryophyllum pin-
natum is due to the ability of quercetin 3-O-α-L-arabinopyranosyl-(1 → 2)-O-α-L-
rhamnopyranoside (6) to inhibit PDE4B, a prominent target in the pathogenesis of 
psoriatic arthritis, and atopic dermatitis [23, 24]; also, the antiaging effect of allicin 
was linked to its ability to act as leukocyte elastase inhibitor [25].
Bagherzadeh et al. applied pharmacophore and structure-based virtual screen-
ing to identify tyrosinase inhibitor from zinc database; among them, five com-
pounds showed the potential to be used as potent inhibitor according to molecular 
Figure 2. 
Ligand-based approaches depend on the elucidation of structural features that could be found in set of active 
drugs (fingerprint) so that compounds possessing the same pharmacophores could be identified.
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dynamic simulation [26]. Interestingly, Choi et al. used structure-based virtual 
screening for repurposing thiopurine drugs such as mercaptopurine (7) as tyrosi-
nase inhibitors for treatment of hyperpigmentation [27]. The chemical structure of 
compounds (1–7) is shown in Figure 4.
2.1.2 Off-target-based repositioning
The ability of most of drugs to induce side effects is originated from their bind-
ing with other targets that might share certain homology with the original targets, 
Figure 3. 
Structure-based virtual screening employ two main approaches: (i) molecular docking where databases 
of thousands of compounds could be docked to the active site of target of interest to identify the top ranked 
compounds and (ii) inverse docking, as the name suggests, where compound of interest is docked against a panel 
of different targets to identify new potential targets.
Figure 4. 
Chemical structure of ricinoleic acid (1), acteoside (2), amentoflavone (3), quercetin-3-O-rutinoside 




so it could be quite handful to use this drugs in treatment of diseases where these 
targets are dysregulated.
Spironolactone (8) is an antagonist to aldosterone; so, it is used for treatment of 
hypertension due to its diuretic effect; however, its steroidal nature allows it to act 
as a competitive antagonist at androgenic receptor; so, it was suggested to be used 
in treatment of androgenic alopecia; however, its effects on hair growth patterns 
in males might be not clinically preferable. On the other hand, it proved to be 
significantly effective in treatment of polycystic ovary syndrome and hirsutism in 
females, due to its ability to inhibit hair regrowth in androgen-dependent regions of 
the body, which was proven by several clinical trials.
Another intriguing example for off-targets drug repositioning is doxepin (9) 
which is a tricyclic antidepressant; it prevents reuptake of serotonin and norepineph-
rine, leading to an increase in the synaptic concentrations of those neurotransmitters. 
Nevertheless, there are several off-target effects that are associated with the use of 
this class of drugs, which are mainly mediated by muscarinic and histamine recep-
tors. This could be explained by its high affinity to H1 receptor which is much higher 
than hydroxyzine by 56 times and diphenhydramine 800 times; such observation 
opened the gate to the FDA approval for treatment of dermatological conditions such 
as pruritus, psychodermatosis, and chronic urticaria as topical and systemic agents.
Off-target effects are also influenced by the route of administration; sodium 
valproate (10), an anti-epileptic drug, inhibits the cellular sodium influx by block-
ing voltage-dependent sodium channels and induces chloride influx by gamma 
hydroxyl butyric acid (GABA)-mimetic effect. It also reduces the release of GABA, 
thereby attenuating neuronal excitation induced by glutamate receptors. It was 
reported by several clinical trials that oral administration of valproate could induce 
hair loss in dose-dependent manner by decreasing biotinidase activity leading to 
alopecia induced by biotin deficiency.
However, sodium valproate topical treatment induced hair growth in male C3H 
mice model, which could be explained by its ability to inhibit glycogen synthase 
kinase 3β and activation of Wnt/β-catenin pathway, which in turn, is associated with 
hair regeneration and anagen induction. This result was supported by randomized 
interventional study, where 7.2% spray of sodium valproate applied twice daily on 
scalp up to 24 weeks showed the efficacy of valproate spray on androgenic alopecia.
Dapsone (11), which is known to be one of the few agents used to fight leprosy, 
was developed as an antistreptococcal agent by targeting dihydropteroate syn-
thetase in bacteria; it was only matter of time until its anti-inflammatory effect 
was noticed due to its effect on numerous neutrophil-mediated and autoimmune 
processes; so, it is now used for recurring neutrophilic dermatosis, cicatricial 
pemphigoid, linear IgA dermatosis, IgA pemphigus, erythema elevatum diutinum, 
acropustulosis infantilis, and prurigo pigmentosa [28].
Finally, thalidomide (12) is a distinguishable case in drug repositioning; it was 
used for treatment of morning sickness in pregnant women after its withdrawal due 
its teratogenic effect; such side effect was studied thoroughly and explained by the 
ability of the drug to inhibit vascular endothelial growth factor (VEGF) which has a 
significant role in angiogenesis and embryo development; so, this drug was reposi-
tioned for treatment of multiple myeloma; also, it was found that thalidomide is a 
strong inhibitor for tumor necrosis factor alpha (TNF-α) and was approved by FDA 
for management of erythema nodosum leprosum [29, 30]. The chemical structure 
of compounds (8–13) is presented in Figure 5.
2.1.3 New target indication-based repositioning
In this approach, data analysis based on omics is used to identify new function 
instead of finding new targets for certain chemical entity; hence, it might be the 
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most challenging approach as it depends on the advances of molecular biology tools 
which can reveal the role of already known target in completely different diseases.
Finasteride (13) is a drug that was developed for treatment of benign prostatic 
hyperplasia, by acting as 5α-reductase enzyme inhibitor; this enzyme was found 
later to be contributing in the development of androgenic alopecia; hence, finaste-
ride at low doses was repositioned to treatment of baldness in men.
Another example is the repositioning of eflornithine (14), which was used 
for treatment of African trypanosomiasis by inhibiting ornithine decarboxylase; 
several years later, the homolog enzyme in humans was found to be responsible for 
hair growth and eflornithine was suggested as potential treatment of hirsutism in 
woman due to its ability to reduce hair growth. This observation was supported by 
several clinical trials and is currently marketed as topical preparation.
Zileuton (15) is a 5-lipoxygenase inhibitor which is used for treatment of 
asthma, by blocking the biosynthesis of leukotriene B4, which contributes 
significantly in tissue inflammation in acne; so, several studies on the experi-
mental and clinical levels have been performed to understand its mode of action, 
as well as safety of this compound in the management of acne vulgaris. Zileuton 
demonstrated a significant efficiency in patients with moderate acne, whereas 
a decrease in inflammatory lesions was noticed in comparison to the placebo 
group. Also, the tolerability and safety of zileuton were satisfactory in all con-
ducted clinical studies [31]. The chemical structure of compounds (13–15) is 
shown in Figure 6.
Figure 5. 
Chemical structure of spironolactone (8), doxepin (9), sodium valproate (10), dapsone (11), and  
thalidomide (12).
Figure 6. 




Chemical structure of resveratrol (16), tiabendazole (17), monobenzone (18), parthenolide (18), doxycycline 
(19), methotrexate (20) prednisone (21), triamcinolone (22), budesonide (23), hydroxychloroquine (24), and 
leflunomide (25).
2.2 Disease-centered drug repositioning
2.2.1 Application of data mining and omics in drug repositioning
In disease-centered paradigm, the observation and analysis of data from phe-
notypic assays, clinical trials, and literature could be an important resource for 
drug repositioning, as previously mentioned, this type of repositioning is oriented 
toward the clinical outcomes rather than the exact molecular mechanism behind the 
drug switch; from other angle, the researcher aims to find certain fingerprint on 
the genetic or proteomic level to support the repositioning hypothesis; for example, 
the transcriptomic analysis of different types of autoimmune diseases could reveal 
similar pattern of gene expression, which means that the same drug could be used 
for different types of immunity-related condition.
Qu et al. applied integrative clinical transcriptomic analyses for finding new drugs 
for treatment of psoriasis. First, gene expression analysis of samples collected from 
psoriasis patient and normal volunteers were used to identify molecular targets asso-
ciated with the disease, and then, connectivity map analysis revealed potential drugs 
for the identified targets, which were resveratrol (16), tiabendazole (17), monoben-
zone (18), parthenolide (18), doxycycline (19), and methotrexate (20) [32].
Also, Patrick et al. gathered drug-related information from more than 20 million 
articles using machine learning based on word embedding to build a model that 
highlights drug-disease relationship in order to repurpose drugs for treatment of 
immune-mediated dermatological conditions, where prednisone (21), triamcino-
lone (22), budesonide (23), hydroxychloroquine (24), and leflunomide (25) were 
among the top five predicted drugs for treatment of psoriasis [33]. The chemical 
structure of compounds (15–25) is demonstrated in Figure 7.
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2.2.2 Clinical observation-based drug repurposing
Bimatoprost (26), a prostaglandin analog, was used for treatment of glaucoma 
patient, but several clinical observations reported the occurrence of eyelash hyper-
trichosis; so, it was used for induction of eyelash regrowth in alopecia areata and for 
cosmeceutical purposes [34, 35].
Phenytoin (27) is one of the first discovered antiepileptic drugs; after its 
introduction to the market, gingival hyperplasia was reported as a side effect for the 
treatment, which triggered dermatologist to evaluate its ability to heal wounds; so, 
phenytoin has been evaluated by several clinical studies, where it proved to be use-
ful in treatment of wounds in topical and oral forms; however, the exact mechanism 
of action is still ambiguous [36].
Bevacizumab, a monoclonal antibody that is used for treatment of several types of 
cancer, was observed to achieve complete remission of psoriasis in metastatic colon 
cancer without any other treatment for psoriasis [37]; a case which was reported 
again in another study that described the same effect in metastatic renal cell cancer, 
psoriasis, and psoriatic arthritis patient, which means the bevacizumab could be 
repurposed for treatment of these dermatoses; also, it sheds the light on the impor-
tance of (VEGF) as a target for treatment of inflammatory skin conditions [38].
The Janus kinase (JAK) inhibitor, tofacitinib (28), was developed originally for 
management of rheumatoid arthritis, ulcerative colitis and other autoimmune dis-
eases, but it was repurposed for psoriasis and atopic dermatitis since JAK was found 
to be contributing in the pathogenesis of these diseases, and currently, several 
clinical trials were performed to assess its clinical significance and concluded that 
response rates in tofacitinib-treated group were significantly higher compared to 
that in placebo [39–41].
Metformin (29), a type-2 diabetes medication, reduces insulin resistance; however, 
its mechanism is not completely understood; so, it was suggested as a treatment of 
several dermatological conditions associated with insulin resistance such as acanthosis 
nigricans and acne; this was supported by several clinical trials where the patients 
showed complete resolution. It also was employed in treatment of hyperpigmentation 
due to its inhibitory effect on tyrosinases, the key enzymes in melanin biosynthesis. 
The anti-melanogenic effect of metformin was demonstrated experimentally on 
human skin biopsies and reconstituted human epidermis; also, clinical trials showed 
that metformin efficacy is comparable to TCC in treating melasma [42–44].
Finally, minoxidil (30), which is a well-known case in drug repositioning, 
was initially used for treatment of hypertension since its strong vasodilator effect 
but during clinical trials, hair regrowth was noticed in patients with androgenic 
alopecia such effect is contributed by stimulating the vascular bed nearby the hair 
follicles which lead to better environment for hair growth. It was suggested that the 
ability of minoxidil to activate cytoprotective prostaglandin synthase-1 and stimu-
late adipose-derived stem cells (ASCs) [45, 46].
2.2.3 Phenotypic screening for drug repositioning
Niclosamide (NCL) (31) is an anti-helminthic drug that has been utilized 
for long time with considerable safety profile; several studies reported its anti-
inflammatory and anticancer activities, highlighting the potential of repurposing 
for different indications; Thatikonda et al. used imiquimod (IMQ )-induced BALB/c 
mouse model to evaluate the efficacy of NCL for treatment of psoriasis, where it 
alleviated epidermal hyperplasia and inflammation induced by IMQ via down-
regulating p65, STAT3, NFATc-1, and NF-κB transcription factors along with Ki-67, 




Chemical structure of bimatoprost (26), phenytoin (27), tofacitinib (28), metformin (29), minoxidil (30), 
niclosamide (31), carvedilol (32), and cannabidiol (CBD) (33).
Hall et al. used zebrafish neutrophil migration assay, for evaluation of the 
suppressive effect of 1280 approved drugs on recruitment of neutrophils; where 
drugs showing prominent anti-inflammatory activity were further tested in atopic 
dermatitis animal model, among them 11 drugs which was not reported previously 
as anti-inflammatory agent [48].
Chang et al. used in vivo model of chemically induced murine skin tumorigen-
esis to confirm the hypothesis of repositioning of beta blocker for treatment of skin 
cancer, since several studies showed that stress-related catecholamine hormone 
expression can affect tumor progression [49].
Carvedilol (32), when administrated orally and topically, prevented DMBA-
induced epidermal hyperplasia, suggesting that it may serve as a new agent for 
protecting against skin cancer [50], which was supported by another study that dem-
onstrated the preventive effect of carvedilol applied topically after UV exposure; so, it 
can be repositioned as prophylactic agent against skin inflammation and cancer [51].
Cannabidiol (CBD) (33) is a nonpsychoactive phytocannabinoid found in 
Cannabis sativa. It is approved recently for the treatment of seizures associated 
with two uncommon and serious forms of epilepsy, Dravet syndrome, and Lennox-
Gastaut syndrome. Oláh et al. reported that CBD-treated human sebocytes and 
human skin organ in vitro showed strong antiproliferative, lipostatic, and anti-
inflammatory effects mediated by a plethora of receptors, ion channels, and other 
components of the endocannabinoid system [52]. These findings were confirmed 
later by clinical trial showing that CBD administrated as an ointment is an effec-
tive and noninvasive option for enhancing the quality of life in patients with some 
skin disorders, especially those with inflammatory background [53]. The chemical 
structure of compounds (26–33) is depicted in Figure 8.
3. Concluding remarks and future perspective
Drug repositioning is an important strategy to maximize the benefits from 
already approved drugs; it will not only contribute to reduction of time and cost 
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